Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.30 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24345303 | 0.92 | MAPT (0.31) | CFTRMAPTALDH1A1HPGDMAPK1 | |
| SCHEMBL23717101 | 0.90 | CFTR (0.34) | CFTR | |
| SCHEMBL23717324 | 0.88 | CFTR (0.31) | CFTRMAPTGABRA5 | |
| SCHEMBL23717045 | 0.88 | POLB (0.37) | CFTRALDH1A1HPGDGABRA5 | |
| SCHEMBL23685145 | 0.87 | CFTR (0.32) | CFTRGABRA5 | |
| SCHEMBL23717303 | 0.84 | CFTR (0.31) | CFTRMAPTALDH1A1HPGDMAPK1 | |
| SCHEMBL23717296 | 0.84 | CFTR (0.31) | CFTRMAPTALDH1A1HPGDMAPK1 | |
| SCHEMBL24346367 | 0.83 | CFTR (0.33) | CFTRMAPTALDH1A1HPGDMAPK1 | |
| SCHEMBL23683788 | 0.82 | CFTR (0.33) | CFTR | |
| SCHEMBL23717262 | 0.81 | NAMPT (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119398-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119398-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | CFTR 307/4885MAPT 4216/4885ALDH1A1 1686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.